17.01
Centessa Pharmaceuticals Plc Adr stock is traded at $17.01, with a volume of 1.13M.
It is down -2.97% in the last 24 hours and up +5.19% over the past month.
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.
See More
Previous Close:
$17.53
Open:
$17.55
24h Volume:
1.13M
Relative Volume:
1.12
Market Cap:
$2.28B
Revenue:
-
Net Income/Loss:
$-151.09M
P/E Ratio:
-10.90
EPS:
-1.56
Net Cash Flow:
$-160.51M
1W Performance:
-5.76%
1M Performance:
+5.19%
6M Performance:
+2.29%
1Y Performance:
+39.43%
Centessa Pharmaceuticals Plc Adr Stock (CNTA) Company Profile
Name
Centessa Pharmaceuticals Plc Adr
Sector
Industry
Phone
44 7391 789784
Address
3RD FLOOR, ALTRINCHAM, CHESHIRE
Compare CNTA with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
CNTA
Centessa Pharmaceuticals Plc Adr
|
17.01 | 2.36B | 0 | -151.09M | -160.51M | -1.56 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
![]()
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Centessa Pharmaceuticals Plc Adr Stock (CNTA) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-21-25 | Initiated | Truist | Buy |
May-28-25 | Initiated | Needham | Buy |
May-08-25 | Initiated | Chardan Capital Markets | Buy |
Mar-31-25 | Initiated | Piper Sandler | Overweight |
Jan-07-25 | Initiated | TD Cowen | Buy |
Sep-20-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Sep-19-24 | Initiated | B. Riley Securities | Buy |
Jul-18-24 | Initiated | Oppenheimer | Outperform |
Nov-15-23 | Upgrade | Jefferies | Hold → Buy |
Oct-26-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
Jun-21-23 | Initiated | Evercore ISI | Outperform |
Jun-12-23 | Initiated | Guggenheim | Buy |
Mar-17-23 | Initiated | SVB Securities | Outperform |
Aug-12-22 | Downgrade | Morgan Stanley | Overweight → Underweight |
Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
Jun-03-22 | Downgrade | Jefferies | Buy → Hold |
Feb-11-22 | Initiated | Goldman | Neutral |
View All
Centessa Pharmaceuticals Plc Adr Stock (CNTA) Latest News
FY2025 Earnings Estimate for CNTA Issued By Chardan Capital - Defense World
Equities Analysts Issue Forecasts for CNTA FY2025 Earnings - Defense World
Centessa Pharma general counsel sells $103k in shares By Investing.com - Investing.com South Africa
Centessa Pharma general counsel sells $103k in shares - Investing.com
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025 - Placera.se
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025 - GlobeNewswire Inc.
Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Given Average Recommendation of “Buy” by Brokerages - Defense World
Bank of New York Mellon Corp Buys Shares of 10,257 Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) - Defense World
Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA): On Track To A Higher Share Price - stocksregister.com
The Future of Centessa Pharmaceuticals plc ADR: Analyzing CNTA - investchronicle.com
Centessa Pharma (CNTA) CBO Weinhoff sells $155,598 in shares By Investing.com - Investing.com India
Centessa Pharma (CNTA) CBO Weinhoff sells $155,598 in shares - Investing.com
Cerity Partners LLC Invests $471,000 in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) - Defense World
Centessa Pharmaceuticals plc ADR Inc. (CNTA) Price Performance: A Fundamental Analysis Perspective - investchronicle.com
Taseko Mines Ltd: Navigating Market Fluctuations with a 1.09B Market Cap - investchronicle.com
Codere Online Luxembourg (NASDAQ:CDRO) & Take-Two Interactive Software (NASDAQ:TTWO) Critical Analysis - Defense World
Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Given Average Rating of “Buy” by Analysts - Defense World
Solid Biosciences Inc. (NASDAQ:SLDB) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Centessa Pharmaceuticals (NASDAQ:CNTA) Shares Down 3.8% After Insider Selling - Defense World
Centessa Pharma (CNTA) CBO Weinhoff sells $138k in shares - Investing.com
Centessa Pharma CEO Saha sells $694,826 in shares - Investing.com
Centessa Pharmaceuticals (CNTA) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Centessa Gets US FDA's Clearance to Start Phase 1 Trial of ORX142 for Neurological, Neurodegenerative Disorders - MarketScreener
Centessa Pharmaceuticals plc Announces Clearance of Investigational New Drug Application for ORX142 - MarketScreener
SEC Form N-CSRS filed by abrdn Life Sciences Investors Shares of Beneficial Interest - Quantisnow
Wall Street Analysts Think Centessa Pharmaceuticals (CNTA) Could Surge 138.77%: Read This Before Placing a Bet - MSN
Centessa Pharmaceuticals Announces Executive Changes By Investing.com - Investing.com South Africa
Centessa Pharmaceuticals Announces Executive Changes - Investing.com India
Earnings Flash (CNTA) Centessa Pharmaceuticals Posts Q1 Net Loss $0.20 a Share, vs. FactSet Est of $0.37 Loss - marketscreener.com
Centessa Pharmaceuticals plc Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Earnings Flash (CNTA) Centessa Pharmaceuticals Posts Q1 License and Other Revenue of $15M - marketscreener.com
Is Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) A Suitable Stock For New Investors Today? - Stocksregister
Ratios in Focus: Analyzing Centessa Pharmaceuticals plc ADR (CNTA)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX
Investor’s Delight: Centessa Pharmaceuticals plc ADR (CNTA) Closes Weak at 13.50, Down -1.53 - DWinneX
Was Centessa Pharmaceuticals plc ADR (CNTA)’s session last reading good? - uspostnews.com
Top investors say Centessa Pharmaceuticals plc ADR (CNTA) ticks everything they need - Sete News
Investor’s Toolkit: Key Ratios for Assessing MSCI Inc (MSCI)’s Performance - DWinneX
Financial Metrics Check: Centessa Pharmaceuticals plc ADR (CNTA)’s Ratios for Trailing Twelve Months - DWinneX
Should investors be concerned about Centessa Pharmaceuticals plc ADR (CNTA)? - uspostnews.com
Parsons Corp (PSN) Shares Up Despite Recent Market Volatility - News Heater
Lantheus Holdings Inc [LNTH] Insider Activity: An Update for Investors - knoxdaily.com
Piper Sandler Initiates Centessa Pharmaceuticals at Overweight With $38 Price Target - MarketScreener
Centessa Pharmaceuticals chief business officer sells $163,386 in stock - Investing.com
Centessa Pharmaceuticals CEO sells shares worth $918,060 By Investing.com - Investing.com South Africa
Centessa Pharmaceuticals CEO sells shares worth $918,060 - Investing.com India
Centessa Pharmaceuticals CAO sells shares worth $120,205 By Investing.com - Investing.com South Africa
Centessa Pharmaceuticals CAO sells shares worth $120,205 - Investing.com India
Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA)’s Stock Boosts 3.25%, But It May Be A Worthy Investment - Stocks Register
Ratios Revealed: Decoding Centessa Pharmaceuticals plc ADR (CNTA)’s Financial Health - The Dwinnex
Centessa Pharmaceuticals officer sells shares worth $588,943 - Investing.com India
Centessa Pharmaceuticals officer Tia Bush sells $185,406 in shares - Investing.com
Centessa Pharmaceuticals Plc Adr Stock (CNTA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Centessa Pharmaceuticals Plc Adr Stock (CNTA) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
HUSSAIN IQBAL J | General Counsel |
Aug 15 '25 |
Sale |
17.23 |
6,000 |
103,380 |
105,386 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):